Lineage Signs an Exclusive Option Agreement with Amasa Therapeutics to Supply and Use of Clinical-Grade Hystem

Published: June 18, 2021 | Tags: Lineage, Option Agreement, Amasa Therapeutics, Clinical-Grade Hystem

BioNTech Reports First Patient Dosing in P-II Clinical Trial of BNT111 to Treat Advanced Melanoma

Published: June 18, 2021 | Tags: BioNTech, P-II, Clinical Trial, BNT111, Advanced Melanoma

CytoReason Collaborates with Sanofi to Initiate its Project Utilizing AI Technology for Asthma

Published: June 18, 2021 | Tags: CytoReason, Project, Utilizing, Sanofi, AI Technology, Asthma

BeiGene Reports First Patient Dosing in P-III AdvanTIG-302 Trial of Ociperlimab (BGB-A1217) + Tislelizumab (BGB-A317) to Treat Non-Small Cell Lung Cancer

Published: June 18, 2021 | Tags: BeiGene, P-III, AdvanTIG-302 Trial, Ociperlimab, BGB-A1217, Tislelizumab, BGB-A317 Non-Small Cell Lung Cancer

Kite Enter into a Partnership with Shoreline Biosciences to Develop Novel Allogeneic Cell Therapies

Published: June 18, 2021 | Tags: Kite, Shoreline Biosciences, Develop, Novel Allogeneic Cell Therapies

Biogen Reports First Patient Dosing in P-III TOPAZ-1 Study of BIIB059 to Treat Systemic Lupus Erythematosus

Published: June 18, 2021 | Tags: Biogen, P-III, TOPAZ-1 Study, BIIB059, Systemic Lupus Erythematosus

Biogen's Gosuranemab (BIIB092) Fails to Meet its Primary Endpoint in P-II TANGO Study for Alzheimer Disease

Published: June 17, 2021 | Tags: Biogen, Gosuranemab, BIIB092, Primary Endpoint, P-II, TANGO Study Alzheimer Disease

Atea Pharma Secures $50M Milestone Payment with Roche in the Development of AT-527 for COVID-19

Published: June 17, 2021 | Tags: Atea Pharma, Milestone Payment, License Agreement, Roche, AT-527

Blueprint Medicines' Ayvakit (avapritinib) Receives FDA's Approval to Treat Patients with Advanced Systemic Mastocytosis

Published: June 17, 2021 | Tags: Blueprint Medicines, Ayvakit, avapritinib, FDA, Approval, Advanced Systemic Mastocytosis

CureVac Report Results of CVnCoV in Second Interim Analysis of P-llb/lll HERALD Trial to Treat COVID-19

Published: June 17, 2021 | Tags: CureVac, Second Interim Analysis, P-llb/lll HERALD Trial, CVnCoV, COVID-19

MannKind and United Therapeutics Reports the US FDA’s Acceptance of NDA for Priority Review of Tyvaso DPI to Treat PAH and PH-ILD

Published: June 17, 2021 | Tags: MannKind, United Therapeutics, US, FDA, Acceptance, NDA, Priority Review, Tyvaso DPI, PAH, PH-ILD

Pfizer Presents Results of Tofacitinib in STOP-COVID Study for Patients Hospitalized with COVID-19 Pneumonia at NEJM

Published: June 17, 2021 | Tags: Pfizer, Tofacitinib, STOP-COVID Study, COVID-19 Pneumonia, NEJM

Lundbeck Presents Results of Vyepti (eptinezumab-jjmr) in RELIEF Study for Preventive Treatment of Migraine at JAMA

Published: June 16, 2021 | Tags: Lundbeck, Vyepti, eptinezumab-jjmr, RELIEF Study, Migraine, JAMA

Organicell Reports Results of Expanded Access Trial for Zofin to Treat Mild to Moderate COVID-19

Published: June 16, 2021 | Tags: Organicell, Expanded Access Trial, Zofin, COVID-19

Regeneron Reports Results of REGEN-COV (casirivimab and imdevimab) in P-III RECOVERY Trial for COVID-19 Patients

Published: June 16, 2021 | Tags: Regeneron, REGEN-COV, Casirivimab, Imdevimab, P-III, RECOVERY Trial, COVID-19

Gilead and Jounce's JTX-1811 Receives US FDA's IND Clearance for Cancer Immunotherapies

Published: June 16, 2021 | Tags: Gilead, Jounce, JTX-1811, US, FDA, IND, Clearance, Cancer Immunotherapies

Linnaeus Therapeutics Reports the Expansion of Clinical Collaboration with Merck to Evaluate LNS8801 + Keytruda for the Treatment of Patients with Advanced Cancer

Published: June 16, 2021 | Tags: Linnaeus Therapeutics, Clinical Collaboration, Merck, LNS8801, Keytruda, Advanced Cancer

Innovent Reports First Patient Dosing in P-II Clinical Trial for the Treatment of Obesity in China

Published: June 16, 2021 | Tags: Innovent, P-II, Clinical Trial, Obesity, China

Sage and Biogen Report Results of Zuranolone in P-III WATERFALL Study for Major Depressive Disorder

Published: June 15, 2021 | Tags: Sage, Biogen, Zuranolone, P-III, WATERFALL Study, Depressive Disorder

AstraZeneca's AZD7442 Fails to Meet its Primary Endpoint in P-III STORM CHASER Study for the Prevention of Symptomatic COVID-19

Published: June 15, 2021 | Tags: AstraZeneca, AZD7442, P-III, STORM CHASER Study, Symptomatic COVID-19

BeiGene's Tislelizumab in Combination with Asieris' APL-1202 Receive the US FDA's IND Approval for MIBC

Published: June 15, 2021 | Tags: BeiGene, Tislelizumab, Asieris, APL-1202, US, FDA, IND, Approval,  MIBC

AstraZeneca's AZD7442 Fails to Meet its Primary Endpoint in P-III STORM CHASER Study for the Prevention of Symptomatic COVID-19

Published: June 15, 2021 | Tags: AstraZeneca, AZD7442, P-III, STORM CHASER Study, Symptomatic COVID-19

Novavax's COVID-19 Vaccine Demonstrates 90.4% Efficacy in P-III PREVENT-19 Study

Published: June 15, 2021 | Tags: Novavax, COVID-19 Vaccine, 90.4% Efficacy, P-III, PREVENT-19 Study

Biogen's BIIB111 Fails to Meet its Primary Endpoint in P-III STAR Study for Choroideremia

Published: June 15, 2021 | Tags: Biogen, BIIB111, Primary Endpoint, P-III, STAR Study,  Choroideremia

GSK Signs an Agreement with iTeos to Develop and Commercialize EOS-448 for Patients with Cancer

Published: June 14, 2021 | Tags: GSK, iTeos Therapeutics, Co-Develop, Commercialize, EOS-448, Cancer

Kite Presents Results of Yescarta (axicabtagene ciloleucel) in P-II ZUMA-5 Trial for R/R Follicular Lymphoma at EHA 2021

Published: June 14, 2021 | Tags: Kite, Yescarta, axicabtagene ciloleucel, P-II, ZUMA-5 Trial, R/R Follicular Lymphoma, EHA 2021

AbbVie Presents Results of Imbruvica (ibrutinib) + Venclexta/Venclyxto in P-III GLOW Study as 1L Treatment for CLL or SLL at EHA 2021

Published: June 14, 2021 | Tags: AbbVie, Imbruvica, ibrutinib, Venclexta, Venclyxto, venetoclax, P-III, GLOW Study, CLL, SLL, EHA 2021

Janssen Presents Results of Darzalex (daratumumab) in P-III MAIA Study for Transplant Ineligible Patients with Multiple Myeloma at EHA 2021

Published: June 14, 2021 | Tags: Janssen, Darzalex, daratumumab, P-III, MAIA Study, Multiple Myeloma, EHA 2021

Celltrion Presents Real-World Data of Truxima (biosimilar, rituximab) for Diffuse Large B-Cell Lymphoma at EHA 2021

Published: June 14, 2021 | Tags: Celltrion Healthcare, Truxima, biosimilar, rituximab, Diffuse Large B-Cell Lymphoma, EHA 2021

Sanofi Presents Results of Sutimlimab in P-III CADENZA Trial to Treat Hemolysis Patients with Cold Agglutinin Disease at EHA 2021

Published: June 14, 2021 | Tags: Sanofi, Sutimlimab, Part A, P-III, CADENZA Trial, Hemolysis, Cold Agglutinin Disease, EHA 2021

Related Post: PharmaShots Weekly Snapshots (June 07 - 11, 2021)